Evidence map›Paper›PMID 18815745›Full record

ReviewImmunologic research2008

X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses.

Hamid Bassiri, W C Janice Yeo, Jennifer Rothman, Gary A Koretzky, Kim E Nichols

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Genetics of Primary Hemophagocytic Lymphohistiocytosis.Advances in experimental medicine and biology · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. EBV Persistence--Introducing the Virus.Current topics in microbiology and immunology · 2015
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hamid BassiriInfectious Diseases Fellowship Training Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
W C Janice Yeo
Jennifer Rothman
Gary A Koretzky
Kim E Nichols
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major focus of our research is to understand the molecular and cellular basis of X-linked lymphoproliferative disease (XLP), a rare and often fatal immunodeficiency caused by mutations in the SH2D1A gene, which encodes the adaptor molecule SAP. Recently, we observed that SAP is essential for the development of natural killer T (NKT) cells, a lymphocyte population that participates in protection against certain tumors, infections, and autoimmune states. In this review, we describe the approaches that we are taking to understand the role of SAP in immune cells, including NKT cells. By using SAP as the focal point of our studies, we hope to identify novel signaling pathways that could be targeted to improve the treatment for patients with XLP as well as more common disorders, such as autoimmunity and cancer.

Indexed as

AnimalsAntibody FormationHumansIntracellular Signaling Peptides and ProteinsKiller Cells, NaturalLymphoproliferative DisordersMutationNeoplasmsSignaling Lymphocytic Activation Molecule Associated ProteinT-LymphocytesVirus DiseasesIntracellular Signaling Peptides and ProteinsSH2D1A protein, humanSignaling Lymphocytic Activation Molecule Associated Protein

Identifiers

PMID18815745
OpenAlexW2093773214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.